Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Beta-lactamase hydrolysis and inhibition studies of the new 1-carbacephem LY163892.

Literature DB >> 3501757

Beta-lactamase hydrolysis and inhibition studies of the new 1-carbacephem LY163892.

Abstract

A novel 1-carbacephem, LY163892, was determined to be more stable to plasmid-mediated beta-lactamases than cefaclor. Chromosomal-mediated Type Ia and IVc enzymes destroyed LY163892 at rates ranging from 16 to 93% that of nitrocefin. LY163892 showed minimal ability to inhibit beta-lactamases other than Type Ia (P99).

Entities: Chemical

Mesh：

Substances：

Year: 1987 PMID： 3501757 DOI： 10.1007/BF02014248

Source DB: PubMed Journal: Eur J Clin Microbiol ISSN： 0722-2211 Impact factor: 3.267

5 in total

1. Stability and blood level determinations of cefaclor, a new oral cephalosporin antibiotic.

Authors: M A Foglesong; J W Lamb; J V Dietz
Journal: Antimicrob Agents Chemother Date: 1978-01 Impact factor: 5.191

2. Summary of laboratory studies on the antibacterial activity of cefaclor.

Authors: D A Preston
Journal: Postgrad Med J Date: 1979 Impact factor: 2.401

3. BMY 28100, a new oral cephalosporin.

Authors: F Leitner; T A Pursiano; R E Buck; Y H Tsai; D R Chisholm; M Misiek; J V Desiderio; R E Kessler
Journal: Antimicrob Agents Chemother Date: 1987-02 Impact factor: 5.191

Review 4. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.

Authors: R N Jones; C Thornsberry
Journal: Rev Infect Dis Date: 1982 Sep-Oct

5. In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin.

Authors: R N Jones; A L Barry; C Thornsberry; H W Wilson
Journal: Antimicrob Agents Chemother Date: 1981-12 Impact factor: 5.191

5 in total

8 in total

1. Susceptibility of new beta-lactams to the expanded-spectrum beta-lactamase CTX-1.

Authors: D Sirot; C Chanal; R Labia; J Sirot
Journal: Infection Date: 1989 Jan-Feb Impact factor: 3.553

2. beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.

Authors: C C Sanders
Journal: Antimicrob Agents Chemother Date: 1989-08 Impact factor: 5.191

3. Pharmaceutical properties of loracarbef: the remarkable solution stability of an oral 1-carba-1-dethiacephalosporin antibiotic.

Authors: C E Pasini; J M Indelicato
Journal: Pharm Res Date: 1992-02 Impact factor: 4.200

Beta-lactamase hydrolysis and inhibition studies of the new 1-carbacephem LY163892.

1. Stability and blood level determinations of cefaclor, a new oral cephalosporin antibiotic.

2. Summary of laboratory studies on the antibacterial activity of cefaclor.

3. BMY 28100, a new oral cephalosporin.

Review 4. Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.

5. In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin.

1. Susceptibility of new beta-lactams to the expanded-spectrum beta-lactamase CTX-1.

2. beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.

3. Pharmaceutical properties of loracarbef: the remarkable solution stability of an oral 1-carba-1-dethiacephalosporin antibiotic.

Review 4. Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

5. Loracarbef versus penicillin V in the treatment of streptococcal pharyngitis and tonsillitis.

6. Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.

7. Disk diffusion susceptibility testing for LY163892 (KT-3777), a new orally administered 1-carbacephem.

8. Pharmacokinetics of LY163892 in infants and children.